ACP 196 Alone or in Combination With Rituximab in Follicular Lymphoma

Trial Profile

ACP 196 Alone or in Combination With Rituximab in Follicular Lymphoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs Acalabrutinib (Primary) ; Rituximab
  • Indications Follicular lymphoma
  • Focus Adverse reactions
  • Sponsors Acerta Pharma
  • Most Recent Events

    • 06 Nov 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Apr 2022.
    • 01 Dec 2016 Status changed from recruiting to active, no longer recruiting.
    • 24 Jun 2015 Planned number of patients changed from 32 to 36 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top